Spending power
TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.
Spending power
Key facts
Counted staff
60
self-reported 51–200 band
Founded
1998
28 years
Registry matches
2
ABR
Office countries
2
2 addresses
Funding rounds
None on record
Company type
Public Company
self-reported
Legal entities
1 brand → 2 possible registrationsThe join is a normalised name comparison against ABR. Treat every row below as a lead to verify, not as an established identity.
Syntara Pty Ltd
ABN96129548858
SYNTARA LIMITED
ABN75082811630
Legal entities
Show as table · Syntara: 2 registry entities
| Syntara Pty Ltd | ABN 96129548858 |
|---|---|
| SYNTARA LIMITED | ABN 75082811630 |
| Confirmed matches | 0 of 2 |
A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.
Description
Syntara Limited (ASX:SNT) is a clinical stage drug development company targeting extracellular matrix dysfunction with its world-leading expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis.
Syntara is managing three phase 2 clinical studies in diseases of high unmet need with a further two potential phase 1c/2 studies being evaluated for 2024. Lead candidate SNT‐5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. SNT-5505 has already achieved FDA Orphan Drug Designation and clearance under an Investigational New Drug Application for development in myelofibrosis. After encouraging phase 2a trial results when used as a monotherapy in myelofibrosis, SNT-5505 is now being studied with a JAK inhibitor in a further phase 2 myelofibrosis study with interim data by Q4 2024. The protocol for another phase 1c/2 study with SNT-5505 in patients with a blood cancer called myelodysplastic syndrome is in development and expected to commence recruitment in 2H 2024.
Syntara is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs as part of an ongoing collaboration with Professor Fiona Wood and the University of Western Australia. SNT‐4728 is being studied in collaboration with Parkinson’s UK as a best-in-class SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation.
Other Syntara drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Syntara developed two respiratory products available in world markets (Bronchitol® for cystic fibrosis and Aridol®- a lung function test), for which it receives royalties.
Specialties
All 16 specialties
- Undertreated Respiratory Diseases
- Research and Development
- inflammation
- cancer
- fibrosis
- cystic fibrosis
- myelofibrosis
- drug discovery
- Fibrosis
- biotechnology
- drugdevelopment
- clinicaltrials
- biotech
- bloodcancer
- scarmanagement
- MDS
Locations
2
Countries with an office address2 addresses on record
AustraliaprimaryUnited Kingdom
Country footprint
Show as table · Offices in 2 countries
| Countries | 2 |
|---|---|
| Primary country | AU |
All codes: AU GB
Addresses
- AU20 Rodborough Rd; Frenchs Forest, NSW 2086Primary
- GBPharmaxis Pharmaceuticals Limited; 25 Moorgate; London, EC2R 6AY
Grid intelligence Members
Signals & hiring
Hiring, headcount and registry-change signals, streamed to members.
Latest signal
Hiring activity
Headcount trend
Financials
Registry-filed capital and financial indicators, standardised by TheGrid.
Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
People & contacts
4 employee profiles on record · names withheld.
Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.
The people relation is never requested, so there is nothing here to unlock.
FAQ
Which legal entities operate under Syntara?
Two New South Wales entities on the ABR: Syntara Pty Ltd (ABN 96 129 548 858) and SYNTARA LIMITED (ABN 75 082 811 630). Both medium confidence.
How many people work at Syntara?
60 counted staff profiles at January 2026, inside the self-reported 51–200 band.
Where does Syntara have offices?
Two addresses on record across 2 countries. Primary: 20 Rodborough Rd, Frenchs Forest, NSW 2086.
Has Syntara raised funding?
None linked to this brand.
What does Syntara list as its specialties?
16 tags on the brand's own list, among them cancer, research and development and biotechnology.
Which companies are listed alongside Syntara?
16 profiles list Syntara as a peer — 91st percentile in Biotechnology. It lists ten peers of its own. Dimerix Limited and BioInnova list it back.